TrialEuropean journal of cancer (Oxford, England : 1990)2023

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.

Sibylle Loibl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.